Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan

Keyphrases

• Nationwide Survey 100%
• Kawasaki Disease 100%
• Survey in Japan 100%
• Infliximab 100%
• Coronary Artery Lesions 40%
• Adverse Events 13%
• Additional Treatment 13%
• Illness 6%
• 1-year-olds 6%
• Aging Treatment 6%
• Serious Adverse Events 6%
• Third-line Treatment 6%
• Age of Onset 6%
• Treatment Course 6%
• Fourth Line 6%
• Neutrophil Count 6%
• White Blood Cell Count 6%
• C-reactive Protein Level 6%
• Serum C-reactive Protein 6%
• Blood Test Results 6%
• Afebrile 6%
• Patient Sex 6%
• Lesion Severity 6%
• Infliximab Therapy 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Mucocutaneous Lymph Node Syndrome 100%
• Infliximab 100%
• Artery Lesion 37%
• Adverse Event 18%
• Disease 6%
• C Reactive Protein 6%
• Onset Age 6%

Immunology and Microbiology

• Kawasaki Disease 100%
• Infliximab 100%
• Coronary Artery 37%
• Leukocyte Count 6%
• C-Reactive Protein 6%
• Neutrophil Granulocyte 6%